MA45189A - Nouveaux dérivés hétérocycliques utiles en tant qu'inhibiteurs de shp2 - Google Patents

Nouveaux dérivés hétérocycliques utiles en tant qu'inhibiteurs de shp2

Info

Publication number
MA45189A
MA45189A MA045189A MA45189A MA45189A MA 45189 A MA45189 A MA 45189A MA 045189 A MA045189 A MA 045189A MA 45189 A MA45189 A MA 45189A MA 45189 A MA45189 A MA 45189A
Authority
MA
Morocco
Prior art keywords
derivatives useful
heterocyclic derivatives
new heterocyclic
shp2 inhibitors
shp2
Prior art date
Application number
MA045189A
Other languages
English (en)
Inventor
Jinlong Bai
Jie Chu
Panliang Gao
Di Kang
Cunbo Ma
Xiaoyan Pei
Chunwei Wen
Xinping Wu
Original Assignee
Jacobio Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jacobio Pharmaceuticals Co Ltd filed Critical Jacobio Pharmaceuticals Co Ltd
Publication of MA45189A publication Critical patent/MA45189A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MA045189A 2016-06-07 2017-06-07 Nouveaux dérivés hétérocycliques utiles en tant qu'inhibiteurs de shp2 MA45189A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2016085122 2016-06-07

Publications (1)

Publication Number Publication Date
MA45189A true MA45189A (fr) 2019-04-10

Family

ID=60578379

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045189A MA45189A (fr) 2016-06-07 2017-06-07 Nouveaux dérivés hétérocycliques utiles en tant qu'inhibiteurs de shp2

Country Status (23)

Country Link
US (1) US10858359B2 (fr)
EP (2) EP3464272B1 (fr)
JP (3) JP6751203B2 (fr)
KR (5) KR20210019607A (fr)
CN (3) CN109311848B (fr)
AU (1) AU2017276457B2 (fr)
CA (1) CA3026784A1 (fr)
CY (1) CY1125042T1 (fr)
DK (1) DK3464272T3 (fr)
EA (3) EA202092441A1 (fr)
ES (1) ES2908801T3 (fr)
HR (1) HRP20220251T1 (fr)
HU (1) HUE057838T2 (fr)
LT (1) LT3464272T (fr)
MA (1) MA45189A (fr)
MX (3) MX388576B (fr)
PH (1) PH12018550202A1 (fr)
PL (1) PL3464272T3 (fr)
PT (1) PT3464272T (fr)
RS (1) RS62987B1 (fr)
SG (2) SG11201810983PA (fr)
SI (1) SI3464272T1 (fr)
WO (1) WO2017211303A1 (fr)

Families Citing this family (157)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11466017B2 (en) 2011-03-10 2022-10-11 Board Of Regents, The University Of Texas System Heterocyclic inhibitors of PTPN11
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
CN109475531B (zh) 2016-05-31 2021-08-17 得克萨斯州立大学董事会 Ptpn11的杂环抑制剂
KR20210019607A (ko) * 2016-06-07 2021-02-22 자코바이오 파마슈티칼스 컴퍼니 리미티드 Shp2 억제제로서 유용한 신규한 헤테로환형 유도체
KR102457146B1 (ko) 2016-06-14 2022-10-19 노파르티스 아게 Shp2의 활성을 억제하기 위한 화합물 및 조성물
IL311645B2 (en) 2016-07-12 2025-11-01 Revolution Medicines Inc 2,5- disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines asallosteric shp2 inhibitors
WO2018057884A1 (fr) 2016-09-22 2018-03-29 Relay Therapeutics, Inc. Inhibiteurs de phosphatase shp2 et leurs procédés d'utilisation
TWI848901B (zh) 2016-10-24 2024-07-21 美商傳達治療有限公司 Shp2磷酸酶抑制劑及其使用方法
KR20190110588A (ko) 2017-01-23 2019-09-30 레볼루션 메디슨즈, 인크. 알로스테릭 shp2 억제제로서의 피리딘 화합물
SG11201906209SA (en) 2017-01-23 2019-08-27 Revolution Medicines Inc Bicyclic compounds as allosteric shp2 inhibitors
NZ758458A (en) * 2017-03-23 2022-07-29 Jacobio Pharmaceuticals Co Ltd Novel heterocyclic derivatives useful as shp2 inhibitors
EP3630770B1 (fr) 2017-05-26 2024-08-28 Relay Therapeutics, Inc. Dérivés de pyrazolo[3,4-b]pyrazine en tant qu'inhibiteurs de la phosphatase shp2
BR112020004246A2 (pt) 2017-09-07 2020-09-01 Revolution Medicines, Inc. composições inibidoras de shp2 e métodos para o tratamento de câncer
US10435389B2 (en) 2017-09-11 2019-10-08 Krouzon Pharmaccuticals, Inc. Octahydrocyclopenta[c]pyrrole allosteric inhibitors of SHP2
EP3687997A1 (fr) 2017-09-29 2020-08-05 Relay Therapeutics, Inc. Dérivés de pyrazolo[3,4-b]pyrazine utilisés en tant qu'inhibiteurs de la phosphatase shp2
CA3078565A1 (fr) 2017-10-12 2019-04-18 Revolution Medicines, Inc. Pyridine, pyrazine et composes de triazine utilises en tant qu'inhibiteurs allosteriques de shp2
KR20200099530A (ko) 2017-12-15 2020-08-24 레볼루션 메디슨즈, 인크. 알로스테릭 shp2 억제제로서의 다환식 화합물
AU2019222026B2 (en) 2018-02-13 2022-05-12 Shanghai Blueray Biopharma Co., Ltd. Pyrimidine-fused cyclic compound, preparation method therefor and application thereof
BR112020017283A2 (pt) 2018-03-02 2020-12-15 Otsuka Pharmaceutical Co., Ltd Compostos farmacêuticos
JP7265275B2 (ja) 2018-03-21 2023-04-26 スージョウ プーヘー バイオファーマ カンパニー リミテッド Ｓｈｐ２阻害剤およびその使用
WO2019183364A1 (fr) 2018-03-21 2019-09-26 Relay Therapeutics, Inc. Inhibiteurs de la phosphatase pyrazolo[3,4-b]pyrazine shp2 et leurs procédés d'utilisation
EP4506035A3 (fr) * 2018-03-21 2025-04-16 Relay Therapeutics, Inc. Inhibiteurs de la phosphatase shp2 et leurs procédés d'utilisation
JP2021521155A (ja) 2018-04-10 2021-08-26 レヴォリューション・メディスンズ，インコーポレイテッド Ｓｈｐ２阻害剤組成物、癌を処置するための方法、およびｓｈｐ変異を有する対象を特定するための方法
JP7297871B2 (ja) 2018-05-02 2023-06-26 ナビール ファーマ，インコーポレイティド Ｐｔｐｎ１１の置換されたヘテロ環式インヒビター
CN110143949A (zh) * 2018-05-09 2019-08-20 北京加科思新药研发有限公司 可用作shp2抑制剂的新型杂环衍生物
MX2021000795A (es) 2018-07-24 2021-04-12 Taiho Pharmaceutical Co Ltd Compuestos heterociclicos para inhibir la actividad de shp2.
EP4356973A3 (fr) * 2018-08-10 2024-06-26 Navire Pharma, Inc. Dérivés de 6-(4-amino-3-méthyl-2-oxa-8-azaspiro[4.5!décan-8-yl)-3-(2,3-dichlorophényl)-2-méthylpyrimidin-4(3h)-one et composés apparentés en tant qu'inhibiteurs de ptpn11 (shp2)
TWI827677B (zh) * 2018-09-18 2024-01-01 美商尼坎醫療公司 作為src同源-2磷酸酶抑制劑之稠合三環衍生物
US20210393623A1 (en) 2018-09-26 2021-12-23 Jacobio Pharmaceuticals Co., Ltd. Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors
CA3113379A1 (fr) * 2018-09-29 2020-04-02 Novartis Ag Procede de fabrication d'un compose pour inhiber l'activite de shp2
WO2020065452A1 (fr) * 2018-09-29 2020-04-02 Novartis Ag Fabrication de composés et de compositions pour inhiber l'activité de shp2
WO2020072656A1 (fr) 2018-10-03 2020-04-09 Gilead Sciences, Inc. Dérivés d'imidozopyrimidine
CN113473990A (zh) 2018-10-08 2021-10-01 锐新医药公司 用于治疗癌症的shp2抑制剂组合物
TW202028183A (zh) * 2018-10-10 2020-08-01 大陸商江蘇豪森藥業集團有限公司 含氮雜芳類衍生物調節劑、其製備方法和應用
CN114341124B (zh) 2018-10-17 2024-09-20 Array生物制药公司 蛋白质酪氨酸磷酸酶抑制剂
CN111138412B (zh) * 2018-11-06 2023-09-15 上海奕拓医药科技有限责任公司 一种螺芳环化合物及其应用
CN113272303B (zh) 2018-11-30 2024-09-17 上海拓界生物医药科技有限公司 嘧啶并五元氮杂环类衍生物、其制备方法及其在医药上的应用
MX2021002804A (es) 2018-12-05 2021-07-15 Mirati Therapeutics Inc Terapias de combinacion.
US20230148450A9 (en) 2019-03-01 2023-05-11 Revolution Medicines, Inc. Bicyclic heteroaryl compounds and uses thereof
WO2020180770A1 (fr) 2019-03-01 2020-09-10 Revolution Medicines, Inc. Composés hétérocyclyle bicycliques et leurs utilisations
CN111647000B (zh) * 2019-03-04 2021-10-12 勤浩医药（苏州）有限公司 吡嗪类衍生物及其在抑制shp2中的应用
JP7734586B2 (ja) 2019-03-07 2025-09-05 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｈｐ２アンタゴニストとしてのカルボキサミド－ピリミジン誘導体
PE20220141A1 (es) 2019-04-02 2022-01-27 Array Biopharma Inc Inhibidores de la proteina tirosina fosfatasa
CA3127475A1 (fr) 2019-04-08 2020-10-15 Merck Patent Gmbh Derives de pyrimidinone utilises en tant qu'antagonistes de shp2
US11453681B2 (en) 2019-05-23 2022-09-27 Gilead Sciences, Inc. Substituted eneoxindoles and uses thereof
CN114245807B (zh) 2019-06-25 2025-05-02 吉利德科学公司 Flt3l-fc融合蛋白和使用方法
AU2020306124A1 (en) 2019-06-28 2022-02-03 Tuojie Biotech (Shanghai) Co., Ltd. Pyrimidine five-membered nitrogen heterocyclic derivative, preparation method thereof and pharmaceutical use thereof
CN111704611B (zh) * 2019-07-25 2022-01-14 上海凌达生物医药有限公司 一类芳基螺环类shp2抑制剂化合物、制备方法和用途
EP3772513A1 (fr) * 2019-08-09 2021-02-10 C.N.C.C.S. S.c.a.r.l. Collezione Nazionale Dei Composti Chimici e Centro Screening Inhibiteurs d'shp2
GB201911928D0 (en) * 2019-08-20 2019-10-02 Otsuka Pharma Co Ltd Pharmaceutical compounds
WO2021043077A1 (fr) * 2019-09-06 2021-03-11 四川科伦博泰生物医药股份有限公司 Composé de pyrazine substituée et procédé de préparation correspondant et son utilisation
EP4034539A1 (fr) 2019-09-24 2022-08-03 Relay Therapeutics, Inc. Inhibiteurs de phosphatase shp2, procédés de production et d'utilisation associés
CN112724145A (zh) * 2019-10-14 2021-04-30 杭州雷索药业有限公司 用于抑制shp2活性的吡嗪衍生物
PH12022550835A1 (en) 2019-10-18 2023-07-03 Forty Seven Inc Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
MY209360A (en) 2019-10-31 2025-07-03 Forty Seven Llc Anti-cd47 and anti-cd20 based treatment of blood cancer
CA3160142A1 (fr) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Inhibiteurs de ras
US11739074B2 (en) 2019-11-04 2023-08-29 Revolution Medicines, Inc. Ras inhibitors
CN120988055A (zh) 2019-11-04 2025-11-21 锐新医药公司 Ras抑制剂
JP7812056B2 (ja) 2019-11-08 2026-02-09 レヴォリューション・メディスンズ，インコーポレイテッド 二環式ヘテロアリール化合物及びその使用
TWI778443B (zh) 2019-11-12 2022-09-21 美商基利科學股份有限公司 Mcl1抑制劑
CN114980976A (zh) 2019-11-27 2022-08-30 锐新医药公司 共价ras抑制剂及其用途
CN117736207A (zh) 2019-12-24 2024-03-22 卡尔那生物科学株式会社 二酰基甘油激酶调节化合物
BR112022010086A2 (pt) 2020-01-07 2022-09-06 Revolution Medicines Inc Dosagem do inibidor de shp2 e métodos de tratamento de câncer
CN113135910A (zh) * 2020-01-19 2021-07-20 北京诺诚健华医药科技有限公司 嘧啶-4(3h)-酮类杂环化合物、其制备方法及其在医药学上的应用
AU2021219668B2 (en) 2020-02-14 2025-06-12 Gilead Sciences, Inc. Antibodies and fusion proteins that bind to CCR8 and uses thereof
CA3173358A1 (fr) 2020-02-28 2021-09-02 Novartis Ag Combinaison pharmaceutique triple comprenant du dabrafenib, un inhibiteur d'erk et un inhibiteur de shp2
WO2021218752A1 (fr) * 2020-04-26 2021-11-04 Betta Pharmaceuticals Co., Ltd Inhibiteurs de shp2, compositions et utilisations de ceux-ci
CN115279749B (zh) * 2020-04-30 2024-05-10 贝达药业股份有限公司 Shp2抑制剂及其组合物和应用
CA3181922A1 (fr) 2020-05-01 2021-11-04 Gilead Sciences, Inc. Composes de 2,4-dioxopyrimidine inhibant cd73
CN113754683A (zh) 2020-06-05 2021-12-07 上海奕拓医药科技有限责任公司 同位素取代的螺芳环化合物及其应用
TW202214253A (zh) 2020-06-18 2022-04-16 美商銳新醫藥公司 延遲、預防及治療對ｒａｓ抑制劑之後天抗性之方法
WO2021259077A1 (fr) * 2020-06-22 2021-12-30 四川科伦博泰生物医药股份有限公司 Composé de pyrazine substitué, composition pharmaceutique le comprenant et utilisation associée
TW202216723A (zh) 2020-07-08 2022-05-01 瑞士商諾華公司 用於抑制shp2活性的化合物及組成物之製造
AU2021344830A1 (en) 2020-09-03 2023-04-06 Revolution Medicines, Inc. Use of SOS1 inhibitors to treat malignancies with SHP2 mutations
MX2023003060A (es) 2020-09-15 2023-04-05 Revolution Medicines Inc Derivados indolicos como inhibidores de ras en el tratamiento del cancer.
EP4267250A1 (fr) 2020-12-22 2023-11-01 Qilu Regor Therapeutics Inc. Inhibiteurs de sos1 et utilisations associées
EP4039685A1 (fr) 2021-02-08 2022-08-10 Irbm S.P.A. Inhibiteurs azabicycliques de shp2
CA3213837A1 (fr) * 2021-03-23 2022-09-29 Shanghai Haiyan Pharmaceutical Technology Co., Ltd. Derive de cetone substitue par un heterocycle, et composition et son utilisation medicinale
EP4067358A1 (fr) 2021-04-02 2022-10-05 C.N.C.C.S. S.c.a.r.l. Collezione Nazionale Dei Composti Chimici e Centro Screening Dérivés de (s)-1-(5-((pyridin-3-yl)thio)pyrazin-2-yl)-4'h,6'h-spiro[pipéridine-4,5'-pyrrolo[1,2-b]pyrazol]-4'-amine et composés similaires en tant qu'inhibiteurs de shp2 pour le traitement par ex. du cancer
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
IL308193A (en) 2021-05-05 2024-01-01 Revolution Medicines Inc RAS inhibitors
AU2022271244A1 (en) 2021-05-05 2023-12-07 Huyabio International, Llc Shp2 inhibitor monotherapy and uses thereof
AU2022271243A1 (en) 2021-05-05 2023-11-30 Huyabio International, Llc Combination therapies comprising shp2 inhibitors and pd-1 inhibitors
WO2022235866A1 (fr) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Inhibiteurs de ras covalents et leurs utilisations
TW202309053A (zh) 2021-05-05 2023-03-01 美商銳新醫藥公司 Ｒａｓ抑制劑
JP7656087B2 (ja) * 2021-05-13 2025-04-02 中国科学院上海薬物研究所 Ｓｈｐ２活性を阻害する複素環化合物、その製造方法および使用
US20220389394A1 (en) 2021-05-18 2022-12-08 Gilead Sciences, Inc. METHODS OF USING FLT3L-Fc FUSION PROTEINS
TW202313041A (zh) 2021-06-09 2023-04-01 瑞士商諾華公司 包含達拉菲尼、曲美替尼和shp2抑制劑之三重藥物組合
TW202317100A (zh) 2021-06-23 2023-05-01 瑞士商諾華公司 包含ｋｒａｓ ｇ１２ｃ抑制劑的藥物組合及其用於治療癌症之用途
KR20240005901A (ko) 2021-06-23 2024-01-12 길리애드 사이언시즈, 인코포레이티드 디아실글리세롤 키나제 조절 화합물
JP7654118B2 (ja) 2021-06-23 2025-03-31 ギリアード サイエンシーズ， インコーポレイテッド ジアシルグリセロールキナーゼ調節化合物
AU2022298639C1 (en) 2021-06-23 2025-07-17 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
KR20240025616A (ko) 2021-06-23 2024-02-27 길리애드 사이언시즈, 인코포레이티드 다이아실글리세롤 키나제 조절 화합물
IL309984A (en) * 2021-07-09 2024-03-01 Kanaph Therapeutics Inc Shp2 inhibitor and use thereof
CN117916242A (zh) * 2021-07-09 2024-04-19 治纳辅医药科技有限公司 Shp2抑制剂及其用途
CN113461538A (zh) * 2021-07-12 2021-10-01 无锡双启科技有限公司 一种2-氯-3-溴苯胺的制备方法
JP2024532374A (ja) 2021-09-01 2024-09-05 ノバルティス アーゲー Ｔｅａｄ阻害剤を含む医薬品組み合わせ物及び癌の治療のためのその使用
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
CN118139858A (zh) 2021-10-28 2024-06-04 吉利德科学公司 吡地嗪-3(2h)-酮衍生物
WO2023077030A1 (fr) 2021-10-29 2023-05-04 Gilead Sciences, Inc. Composés cd73
US20230220106A1 (en) 2021-12-08 2023-07-13 Dragonfly Therapeutics, Inc. Antibodies targeting 5t4 and uses thereof
US20230203202A1 (en) 2021-12-08 2023-06-29 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and 5t4
EP4452414A2 (fr) 2021-12-22 2024-10-30 Gilead Sciences, Inc. Agents de dégradation de doigt de zinc de la famille ikaros et utilisations associées
WO2023122615A1 (fr) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Agents de dégradation des doigts de zinc de la famille ikaros et leurs utilisations
WO2023122938A1 (fr) * 2021-12-28 2023-07-06 Js Innomed Holdings Ltd. Composés hétérocycliques utilisés en tant qu'inhibiteurs de shp2, compositions comprenant le composé hétérocyclique, et leurs procédés d'utilisation
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
CN119136806A (zh) 2022-03-08 2024-12-13 锐新医药公司 用于治疗免疫难治性肺癌的方法
WO2023169170A1 (fr) * 2022-03-10 2023-09-14 捷思英达控股有限公司 Composé hétérocyclique utilisé en tant qu'inhibiteur de shp2, composition comprenant un composé hétérocyclique, et procédé l'utilisant
ES2999273T3 (en) 2022-03-17 2025-02-25 Gilead Sciences Inc Ikaros zinc finger family degraders and uses thereof
CN119031937A (zh) 2022-03-24 2024-11-26 吉利德科学公司 用于治疗表达Trop-2的癌症的联合疗法
TWI876305B (zh) 2022-04-05 2025-03-11 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
KR20250004824A (ko) 2022-04-21 2025-01-08 길리애드 사이언시즈, 인코포레이티드 Kras g12d 조절 화합물
WO2023230205A1 (fr) 2022-05-25 2023-11-30 Ikena Oncology, Inc. Inhibiteurs de mek et leurs utilisations
JP2025521232A (ja) 2022-06-10 2025-07-08 レボリューション メディシンズ インコーポレイテッド 大環状ｒａｓ阻害剤
IL317958A (en) 2022-07-01 2025-02-01 Gilead Sciences Inc CD73 compounds
WO2024040131A1 (fr) 2022-08-17 2024-02-22 Treeline Biosciences, Inc. Inhibiteurs de pyridopyrimidine kras
US20240091351A1 (en) 2022-09-21 2024-03-21 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY
EP4345101A1 (fr) 2022-09-29 2024-04-03 Irbm S.P.A. Dérivés d'azole utilisés en tant qu'inhibiteurs de shp2
JP2025536369A (ja) 2022-10-21 2025-11-05 リーディングタック ファーマシューティカル（シャオシン）カンパニー，リミテッド Ｋｒａｓ ｇ１２ｄ分解剤及びその製造方法並びに応用
JP2025537482A (ja) 2022-10-21 2025-11-18 リーディングタック ファーマシューティカル（シャオシン）カンパニー，リミテッド ｐａｎ－ＫＲＡＳ分解剤及びその製造方法並びに応用
CN115677660B (zh) * 2022-10-27 2024-05-03 中国药科大学 苯基脲类化合物及其制备方法、用途和药物组合物
US20240254118A1 (en) 2022-12-22 2024-08-01 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
JP2026503032A (ja) * 2023-01-05 2026-01-27 カナプ セラピューティクス インコーポレイテッド Ｓｈｐ２阻害剤及びその使用
EP4687905A1 (fr) 2023-03-30 2026-02-11 Revolution Medicines, Inc. Compositions pour induire une hydrolyse de ras gtp et leurs utilisations
WO2024211663A1 (fr) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Composés macrocycliques condensés en tant qu'inhibiteurs de ras
EP4688790A1 (fr) 2023-04-07 2026-02-11 Revolution Medicines, Inc. Composés macrocycliques condensés en tant qu'inhibiteurs de ras
EP4695260A1 (fr) 2023-04-11 2026-02-18 Gilead Sciences, Inc. Composés modulateurs de kras
KR20250169290A (ko) 2023-04-14 2025-12-02 레볼루션 메디슨즈, 인크. Ras 억제제의 결정형, 이를 함유하는 조성물 및 이의 사용 방법
KR20250172857A (ko) 2023-04-14 2025-12-09 레볼루션 메디슨즈, 인크. Ras 억제제의 결정형
KR20250175331A (ko) 2023-04-21 2025-12-16 길리애드 사이언시즈, 인코포레이티드 Prmt5 억제제 및 이의 용도
WO2024229406A1 (fr) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Polythérapie pour une maladie ou un trouble lié à ras
US20250042922A1 (en) 2023-06-30 2025-02-06 Gilead Sciences, Inc. Kras modulating compounds
US20250066328A1 (en) 2023-07-26 2025-02-27 Gilead Sciences, Inc. Parp7 inhibitors
AU2024297978A1 (en) 2023-07-26 2026-02-05 Gilead Sciences, Inc. Parp7 inhibitors
WO2025034702A1 (fr) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 destiné à être utilisé dans le traitement d'une maladie ou d'un trouble lié à une protéine ras
WO2025034919A1 (fr) 2023-08-08 2025-02-13 Quanta Therapeutics, Inc. Polythérapies avec des modulateurs de kras
TW202521120A (zh) * 2023-08-17 2025-06-01 大陸商北京加科思新藥研發有限公司 藥物組合物及其應用
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250101042A1 (en) 2023-09-08 2025-03-27 Gilead Sciences, Inc. Kras g12d modulating compounds
TW202528315A (zh) 2023-09-21 2025-07-16 美商樹線生物科學公司 螺環二氫哌喃并吡啶ＫＲａｓ抑制劑
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025081291A1 (fr) * 2023-10-16 2025-04-24 Canwell Biotech Limited Dérivés de benzo [c] [1, 2] oxaborol-1(3h)-ol utilisés comme inhibiteurs de shp2, compositions et méthodes associées
WO2025096589A1 (fr) 2023-11-03 2025-05-08 Gilead Sciences, Inc. Inhibiteurs de prmt5 et leurs utilisations
WO2025106901A1 (fr) 2023-11-17 2025-05-22 Quanta Therapeutics, Inc. Polythérapies anticancéreuses avec un modulateur de kras et un inhibiteur de la voie rtk-mapk
WO2025137640A1 (fr) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Inhibiteurs azaspiro de wrn
WO2025137507A1 (fr) 2023-12-22 2025-06-26 Regor Pharmaceuticals, Inc. Inhibiteurs de sos1 et leurs utilisations
WO2025171296A1 (fr) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Inhibiteurs de ras
WO2025240847A1 (fr) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Inhibiteurs de ras
WO2025245127A1 (fr) 2024-05-21 2025-11-27 Treeline Biosciences, Inc. Inhibiteurs de dihydropyranopyrimidine kras spirocycliques
WO2025245003A1 (fr) 2024-05-21 2025-11-27 Gilead Sciences, Inc. Inhibiteurs de prmt5 et leurs utilisations
WO2025255438A1 (fr) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Procédés de traitement d'une maladie ou d'un trouble lié à la protéine ras
WO2025265060A1 (fr) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Compositions thérapeutiques et procédés de gestion d'effets liés au traitement
WO2026006747A1 (fr) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Inhibiteurs de ras
WO2026015801A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble liés à ras
WO2026015825A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Utilisation d'un inhibiteur de ras pour traiter le cancer du pancréas
WO2026015790A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble lié à ras
WO2026015796A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble lié à ras

Family Cites Families (174)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3377826B2 (ja) 1993-05-06 2003-02-17 ヘキスト・アクチェンゲゼルシャフト 液晶組成物に使用するための新規化合物
JP2002500618A (ja) 1995-10-31 2002-01-08 イーライ・リリー・アンド・カンパニー 抗血栓性ジアミン
WO2000059884A1 (fr) 1999-01-26 2000-10-12 Dana-Farber Cancer Institute, Inc. Composes pharmaceutiquement actifs et procedes d'utilisation
US7375125B2 (en) 1999-08-04 2008-05-20 Ore Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
EP1415987B1 (fr) 2000-10-20 2007-02-28 Eisai R&D Management Co., Ltd. Composes heteroaromatiques azotes pour le traitement des maladies de cancer
EP1467736A2 (fr) 2001-12-21 2004-10-20 Bayer Pharmaceuticals Corporation Polytherapies antiangiogeneses a base de derives de pyridazine ou pyridine
US6855709B2 (en) 2002-02-22 2005-02-15 Pharmacia & Upjohn Company Pyridyl sulfone derivatives
DE10246657A1 (de) 2002-10-07 2004-04-15 Merck Patent Gmbh Chirales Phenolderivat, dieses enthaltendes Flüssigkristallmedium, Verfahren zur Herstellung eines Flüssigkristallmediums und elektrooptische Flüssigkristallanzeige
CA2500492C (fr) 2002-11-18 2010-03-16 Solomon Ungashe Arylsulfonamides
SE0203712D0 (sv) 2002-12-13 2002-12-13 Astrazeneca Ab Novel compounds
AP2005003365A0 (en) 2003-02-07 2005-09-30 Janssen Pharmaceutica Nv Hiv inhibiting 1, 2, 4-triazines.
WO2004071426A2 (fr) 2003-02-11 2004-08-26 Kemia Inc. Composes destines au traitement d'une infection virale
GB2400101A (en) 2003-03-28 2004-10-06 Biofocus Discovery Ltd Compounds capable of binding to the active site of protein kinases
WO2004099158A1 (fr) 2003-04-30 2004-11-18 Ricerca Biosciences, Llc. N-oxydes monocycliques utilises comme antagonistes des proteines bcl-2
WO2005004810A2 (fr) 2003-07-02 2005-01-20 Merck & Co., Inc. Derives arylsulfonamide
CA2531510A1 (fr) 2003-07-08 2005-01-20 Astrazeneca Ab Derives de spiro '1-azabicyclo '2.2.2!octan-3,5'-oxazolidin -2-one! possedant une affinite avec le recepteur d'acetylcholine nicotinique alpha7
CA2540640A1 (fr) 2003-09-30 2005-04-14 Amgen Inc. Ligands de recepteur vanilloide et leur utilisation dans certains traitements
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
TW200528459A (en) 2004-01-06 2005-09-01 Achillion Pharmaceuticals Inc Azabenzofuran substituted thioureas; inhibitors of viral replication
BRPI0506817A (pt) 2004-01-12 2007-05-29 Cytopia Res Pty Ltd inibidores seletivos de quinase
US7435831B2 (en) 2004-03-03 2008-10-14 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
AU2005219438B2 (en) 2004-03-03 2011-02-17 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
AU2005223610B2 (en) * 2004-03-23 2008-05-29 Banyu Pharmaceutical Co., Ltd. Substituted quinazoline or pyridopyrimidine derivative
JP4865702B2 (ja) 2004-05-03 2012-02-01 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド サイトカイン阻害剤
NZ551603A (en) 2004-06-24 2010-11-26 Incyte Corp N-substituted piperidines and their use as pharmaceuticals
US20070043057A1 (en) 2005-02-09 2007-02-22 Threshold Pharmaceuticals, Inc. Lonidamine analogs
CA2577588C (fr) 2004-10-29 2013-09-10 Tibotec Pharmaceuticals Ltd. Derives de pyrimidine bicycliques inhibant le vih
WO2006063010A2 (fr) 2004-12-08 2006-06-15 Nuada, Llc Composes et procedes d'utilisation
GB0428082D0 (en) 2004-12-22 2005-01-26 Welcome Trust The Ltd Therapeutic compounds
EP2135863A1 (fr) 2004-12-23 2009-12-23 Mallinckrodt, Inc. Dérivés de pyrazine fluorescents et leurs procédés d'utilisation dans l'évaluation de la fonction rénale
US7622583B2 (en) 2005-01-14 2009-11-24 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2
CN101384183B (zh) 2005-02-04 2012-07-04 西诺米克斯公司 包含连接有杂芳基部分的化合物及其作为用于食物组合物的新型鲜味调节剂、促味剂和味觉增强剂的应用
WO2006087305A1 (fr) 2005-02-16 2006-08-24 Neurosearch A/S Derives aryle diazabicycliques et utilisation medicale
WO2007046867A2 (fr) 2005-05-19 2007-04-26 Xenon Pharmaceuticals Inc. Derives de piperidine et leurs utilisations comme agents therapeutiques
CA2609388C (fr) 2005-05-30 2013-08-06 Banyu Pharmaceutical Co., Ltd. Nouveau derive de piperidine
JP2007013804A (ja) 2005-07-01 2007-01-18 Mitsubishi Electric Corp 属性指定通信方法および通信装置
CA2606004A1 (fr) * 2005-08-02 2007-02-08 Neurogen Corporation Dipiperazinyl cetones et analogues apparentes
CA2625189A1 (fr) 2005-10-19 2007-04-26 Gruenenthal Gmbh Nouveaux ligands du recepteur vanilloide et leur utilisation dans la production de medicaments
WO2007057742A2 (fr) 2005-11-18 2007-05-24 Pfizer Products Inc. Nouveaux derives de piperazinone
CA2636314A1 (fr) 2005-11-29 2007-06-07 Toray Industries, Inc. Derive d'arylmethylene uree et utilisation de celui-ci
AU2006328551A1 (en) 2005-12-21 2007-06-28 Janssen Pharmaceutica N.V. Substituted pyrazinone derivatives as alpha2c-adrenoreceptor antagonists
WO2007084728A2 (fr) 2006-01-19 2007-07-26 Abbott Laboratories 2-imino-benzimidazoles
NZ569329A (en) 2006-01-30 2011-09-30 Transtech Pharma Inc Substituted imidazole derivatives and their use as PTPase inhibitors
CA2645137A1 (fr) 2006-03-07 2007-09-13 James F. Blake Derives heterobicycliques de pyrazole et methodes d'utilisation
DE602007007206D1 (de) 2006-04-20 2010-07-29 Janssen Pharmaceutica Nv Substituierte pyrazinonderivate zur verwendung als arzneimittel
MX2008014921A (es) 2006-05-22 2008-12-09 Janssen Pharmaceutica Nv Derivados de piracinona sustituidos para uso como un medicamento.
AR063707A1 (es) 2006-09-11 2009-02-11 Cgi Pharmaceuticals Inc Determinadas amidas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmacéuticas que las comprenden.
US7838523B2 (en) 2006-09-11 2010-11-23 Cgi Pharmaceuticals, Inc. Certain substituted amides, method of making, and method of use thereof
ATE467622T1 (de) 2006-10-04 2010-05-15 Hoffmann La Roche Pyrazin-2-carboxamid-derivate als cb2- rezeptormodulatoren
DE102007018150A1 (de) 2007-04-16 2008-10-23 Grünenthal GmbH VR1-Rezeptor-Liganden und µ-Opioid-Rezeptor-Liganden zur Behandlung von Schmerz
JP2010518083A (ja) 2007-02-12 2010-05-27 メルク・シャープ・エンド・ドーム・コーポレイション ピペリジン誘導体
WO2008104077A1 (fr) 2007-02-28 2008-09-04 Methylgene Inc. Inhibiteurs à petite molécule de protéines arginine méthyltransférases (prmt)
AU2008221263B2 (en) 2007-03-01 2012-02-23 Novartis Ag Pim kinase inhibitors and methods of their use
US8313729B2 (en) 2007-03-01 2012-11-20 Medibeacon, LLC Integrated photoactive small molecules and uses thereof
WO2008112674A1 (fr) 2007-03-12 2008-09-18 Irm Llc Composés et compositions comme inhibiteurs de l'activité du récepteur cannabinoïde 1
CA2698753A1 (fr) 2007-09-06 2009-03-12 Array Biopharma Inc. Pyrazolo-pyridines en tant qu'inhibiteurs de tyrosine kinase
WO2009036066A1 (fr) 2007-09-10 2009-03-19 Curis, Inc. Inhibiteurs du récepteur du facteur de croissance endothélial vasculaire (vegfr) contenant une fraction de liaison au zinc
ES2499018T3 (es) 2007-09-20 2014-09-26 Irm Llc Compuestos y composiciones como moduladores de la actividad de GPR119
EP2386558B1 (fr) 2007-10-18 2014-10-01 Boehringer Ingelheim International GmbH Antagonistes du CGRP
US20100216816A1 (en) 2007-10-24 2010-08-26 Barrow James C Pyrazinyl amide-t type calcium channel antagonists
US20110027264A1 (en) 2008-02-29 2011-02-03 Xianhai Huang Gamma secretase modulators for the treatment of alzheimer's disease
ATE531372T1 (de) 2008-04-07 2011-11-15 Amgen Inc Gem-disubstituierte und spirocyclische aminopyridine/pyrimidine als zellcyclus- inhibitoren
AR071619A1 (es) 2008-05-07 2010-06-30 Galapagos Nv Compuestos de pirazina fusionados utiles para el tratamiento de enfermedades degenerativas e inflamatorias y composiciones farmaceuticas que los contienen.
EP2328586A2 (fr) 2008-05-20 2011-06-08 Cephalon, Inc. Dérivés pyridazinone substitués comme ligands des récepteurs de l'histamine-3 (h3)
KR20110026481A (ko) 2008-06-20 2011-03-15 메타볼렉스, 인코포레이티드 아릴 ｇｐｒ１１９ 작동약 및 이의 용도
PE20110419A1 (es) 2008-08-22 2011-07-13 Novartis Ag Compuestos de pirrolo-pirimidina como inhibidores de cdk
JP5731978B2 (ja) 2008-09-26 2015-06-10 インテリカイン， エルエルシー 複素環キナーゼ阻害剤
JP2012512255A (ja) 2008-12-17 2012-05-31 アムジエン・インコーポレーテツド ホスホジエステラーゼ１０阻害剤としてのアミノピリジンおよびカルボキシピリジン化合物
CA2744935A1 (fr) 2008-12-19 2010-06-24 Boehringer Ingelheim International Gmbh Nouveaux composes
WO2010074244A1 (fr) 2008-12-25 2010-07-01 大正製薬株式会社 Dérivé d'isoquinoléine
KR20110119707A (ko) 2009-01-22 2011-11-02 유니진 래보러토리즈 인코포레이티드 비만 치료
WO2010086613A1 (fr) 2009-01-30 2010-08-05 Betagenon Ab Composés utiles en tant qu'inhibiteurs tel que ampk
AU2010222289B2 (en) 2009-03-13 2013-07-11 Advinus Therapeutics Private Limited Substituted fused pyrimidine compounds
CN102596923B (zh) 2009-07-08 2015-04-29 波罗的海生物公司 1,2,4-噻唑烷-3-酮衍生物及其在癌症治疗中的用途
CA2771190C (fr) 2009-08-17 2020-01-21 Memorial Sloan-Kettering Cancer Center Composes de liaison a une proteine de choc thermique, compositions et procedes pour les fabriquer et les utiliser
EP2473500A2 (fr) 2009-09-01 2012-07-11 Pfizer Inc. Dérivés de benzimidazole
KR20120092629A (ko) 2009-10-09 2012-08-21 아이알엠 엘엘씨 Ｇｐｒ119 활성의 조절제로서의 화합물 및 조성물
US8759377B2 (en) 2009-11-23 2014-06-24 Vanderbilt University Substituted dioxopiperidines and dioxopyrrolidines as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
ES2438509T3 (es) 2009-12-14 2014-01-17 Merck Patent Gmbh Inhibidores de la esfingosina quinasa
CN104341401B (zh) 2009-12-18 2017-02-15 北京凯因科技股份有限公司 C型肝炎病毒复制的新型抑制剂
US8431575B2 (en) 2010-02-18 2013-04-30 Transtech Pharma, Inc. Phenyl-heteroaryl derivatives and methods of use thereof
JP5918214B2 (ja) 2010-04-13 2016-05-18 ノバルティス アーゲー がんを治療するためのサイクリン依存性キナーゼ４またはサイクリン依存性キナーゼ（ｃｄｋ４／６）阻害剤およびｍｔｏｒ阻害剤を含む組合せ
WO2011135276A1 (fr) 2010-04-29 2011-11-03 The University Of Edinburgh (8-aza-bicyclo[3.2.1]oct-8-yl)-[5-(1h-pyrazol-4-yl]-méthanones 3,3-disubstituées en tant qu'inhibiteurs de 11-(bêta)-hsd1
WO2011146401A1 (fr) 2010-05-17 2011-11-24 Intermune, Inc. Nouveaux inhibiteurs de la réplication du virus de l'hépatite c
MX351368B (es) 2010-05-26 2017-10-12 Sunovion Pharmaceuticals Inc Compuestos heteroarilo y metodos para utilizarlos.
EA025611B1 (ru) 2010-07-29 2017-01-30 Райджел Фармасьютикалз, Инк. Активирующие ampk гетероциклические соединения и способы их использования
JP2013230986A (ja) 2010-08-25 2013-11-14 Kyorin Pharmaceutical Co Ltd 新規ヒダントイン誘導体及びそれらを有効成分とする医薬
CN102432598A (zh) 2010-09-29 2012-05-02 江苏恒瑞医药股份有限公司 三环化合物、其制备方法及其在医药上的应用
US20140066431A1 (en) * 2010-11-15 2014-03-06 Exelixis, Inc. Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture
GB201020161D0 (en) 2010-11-26 2011-01-12 Almac Discovery Ltd Pharmaceutical compounds
JP5937102B2 (ja) 2010-12-14 2016-06-22 エレクトロフォレティクス リミテッド カゼインキナーゼ１デルタ（ｃｋ１デルタ）阻害剤
US8987271B2 (en) 2010-12-22 2015-03-24 Eutropics Pharmaceuticals, Inc. 2,2′-biphenazine compounds and methods useful for treating disease
US20120184572A1 (en) 2011-01-13 2012-07-19 Metabolex, Inc. Aryl gpr119 agonists and uses thereof
JP2014515029A (ja) 2011-04-29 2014-06-26 アイカーン・スクール・オブ・メディシン・アト・マウント・シナイ キナーゼ阻害剤
US9586928B2 (en) 2011-05-16 2017-03-07 The Scripps Research Institute Modulators of the nuclear hormone receptor ROR
US20120316182A1 (en) * 2011-06-10 2012-12-13 Calcimedica, Inc. Compounds that modulate intracellular calcium
EP2554544A1 (fr) 2011-08-01 2013-02-06 Almirall, S.A. Dérivés de pyridin-2(1h)-one en tant qu'inhibiteurs de JAK
WO2013039851A1 (fr) 2011-09-12 2013-03-21 Mallinckrodt Llc Agents optiques permettant d'obtenir des images de métalloprotéases matricielles et de les visualiser
MX365923B (es) 2011-12-12 2019-06-20 Celgene Int Ii Sarl Derivados de acido carboxilico que comprenden cuatro ciclos, que actuan como moduladores del receptor del peptido 1 similar al glucagon (glp-1) para terapia de enfermedades como la diabetes.
EP2817388B1 (fr) 2012-02-22 2020-03-25 Merck Patent GmbH Milieu cristallin liquide
GB201204985D0 (en) 2012-03-21 2012-05-02 Genentech Inc Compounds
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
RU2632899C2 (ru) 2012-04-25 2017-10-11 Раквалиа Фарма Инк. Амидопроизводные как блокаторы ttx-s
BR112014027133A2 (pt) 2012-05-09 2017-06-27 Basf Se compostos, composição agrícola ou veterinária, método para o controle das pragas de invertebrados, material de propagação dos vegetais e método para o tratamento ou proteção de um animal.
WO2014000178A1 (fr) 2012-06-27 2014-01-03 Merck Sharp & Dohme Corp. Dérivés de sulfamide et leurs méthodes d'utilisation permettant d'améliorer la pharmacocinétique d'un médicament
US9434725B2 (en) 2012-06-27 2016-09-06 F. Hoffmann-La Roche Ag 5-azaindazole compounds and methods of use
EP3584246A1 (fr) 2012-08-16 2019-12-25 The Scripps Research Institute Nouveaux ligands kappa opioïdes
JOP20130273B1 (ar) 2012-09-11 2021-08-17 Genzyme Corp مثبطات انزيم (سينثاز) غلوكوسيل سيراميد
AU2013341115B2 (en) * 2012-11-09 2016-07-14 Glaxosmithkline Llc Novel compounds as diacylglycerol acyltransferase inhibitors
CN108434149B (zh) 2013-03-15 2021-05-28 G1治疗公司 针对Rb阳性异常细胞增殖的HSPC节制性治疗
RU2015141592A (ru) 2013-03-15 2017-04-21 Ф. Хоффманн-Ля Рош Аг АРИЛ-СУЛЬФАМИДЫ И СУЛЬФАМАТЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ RORc
WO2014184014A1 (fr) 2013-05-15 2014-11-20 Basf Se Composés de n-(1,2,5-oxadiazol-3-yl)carboxamide et leur utilisation en tant qu'herbicides
WO2014184074A1 (fr) 2013-05-15 2014-11-20 Basf Se Composés de n-(tétrazol-5-yl)- et n-(triazol-5-yl)hétarylcarboxamide substitués et leur utilisation en tant qu'herbicides
GB201309508D0 (en) 2013-05-28 2013-07-10 Redx Pharma Ltd Compounds
WO2014201172A1 (fr) 2013-06-11 2014-12-18 Receptos, Inc. Nouveaux modulateurs du récepteur glp-1
AU2014284279A1 (en) 2013-07-03 2016-02-18 Beth Israel Deaconess Medical Center, Inc. SHP2 inhibitors and methods of treating autoimmune and/or glomerulonephritis-associated diseases using SHP2 inhibitors
CN104341386A (zh) * 2013-07-23 2015-02-11 中国科学院上海药物研究所 一类芳基杂环小分子化合物、其衍生物及其制备方法和用途
EP3029031A4 (fr) 2013-07-30 2017-01-11 Takeda Pharmaceutical Company Limited Composé hétérocyclique
EP3027625B1 (fr) 2013-07-31 2018-05-30 Merck Sharp & Dohme Corp. Derives spiro-fusionnes de piperidine utiles dans le traitement, entre autres, de l'hypertension et de l' insuffisance cardiaque aiguë ou chronique
US20150087673A1 (en) 2013-09-26 2015-03-26 Rigel Pharmaceuticals, Inc. Methods for using and biomarkers for ampk-activating compounds
CA2926571C (fr) 2013-10-08 2022-05-17 Qing-bin LU Composes anticancereux non a base de platine destines a etre utilises dans la chimiotherapie-cible
EP3060550B1 (fr) 2013-10-21 2019-05-15 Merck Patent GmbH Composés hétéroaryle servant d'inhibiteurs de la btk et leurs utilisations
US10131841B2 (en) 2013-12-16 2018-11-20 Merck Patent Gmbh Liquid-crystalline medium
WO2015091420A1 (fr) 2013-12-19 2015-06-25 Bayer Pharma Aktiengesellschaft Utilisation de dérivés de bipipéridinyle substitués comme antagonistes des alpha-2c-adrénorécepteurs
EP3094627B1 (fr) 2014-01-17 2018-08-22 Novartis AG Dérivés de 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine et compositions les contenant pour l'inhibition de l'activité de shp2
CN105899493B (zh) 2014-01-17 2019-03-29 诺华股份有限公司 用于抑制shp2活性的1-(三嗪-3-基/哒嗪-3-基)-哌(-嗪)啶衍生物及其组合物
JO3517B1 (ar) * 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
WO2015123437A1 (fr) 2014-02-13 2015-08-20 Incyte Corporation Cyclopropylamines en tant qu'inhibiteurs de lsd1
MA39337B1 (fr) 2014-02-14 2019-11-29 Takeda Pharmaceuticals Co Modulateurs de pyrazines de gpr6
US10000469B2 (en) 2014-03-25 2018-06-19 Duke University Heat shock protein 70 (hsp-70) receptor ligands
CN106132963B (zh) 2014-04-07 2019-08-06 荷兰转化研究中心有限责任公司 (5,6-二氢)嘧啶并[4,5-e]吲嗪
EP3145912A1 (fr) 2014-05-23 2017-03-29 F. Hoffmann-La Roche AG Dérivés de benzène sulfonamide et leur utilisation comme modulateurs de rorc
CN105294655B (zh) 2014-07-26 2019-03-15 广东东阳光药业有限公司 Cdk类小分子抑制剂的化合物及其用途
WO2016022644A1 (fr) 2014-08-06 2016-02-11 Merck Sharp & Dohme Corp. Antagonistes hétérocycliques des récepteurs cgrp
WO2016022645A1 (fr) 2014-08-06 2016-02-11 Merck Sharp & Dohme Corp. Antagonistes hétérocycliques du récepteur du cgrp
EP2985334B1 (fr) 2014-08-15 2018-06-20 Merck Patent GmbH Milieu liquide cristallin
CN112125901A (zh) * 2014-09-05 2020-12-25 赛尔基因昆蒂赛尔研究公司 赖氨酸特异性脱甲基酶-1的抑制剂
WO2016040449A1 (fr) 2014-09-10 2016-03-17 Raze Therapeutics, Inc. Inhibiteurs de la 3-phosphoglycérate déshydrogénase) et leurs utilisations
TWI788655B (zh) 2015-02-27 2023-01-01 美商林伯士拉克許米公司 酪胺酸蛋白質激酶2(tyk2)抑制劑及其用途
JP6726677B2 (ja) 2015-03-11 2020-07-22 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッドChia Tai Tianqing Pharmaceutical Group Co., Ltd. 抗がん剤としての置換２−ｈ−ピラゾール誘導体
JP2018509448A (ja) 2015-03-25 2018-04-05 ノバルティス アーゲー 組合せ医薬
TWI703150B (zh) 2015-06-04 2020-09-01 美商庫拉腫瘤技術股份有限公司 用於抑制ｍｅｎｉｎ及ｍｌｌ蛋白之交互作用的方法及組合物
EP3302057A4 (fr) 2015-06-04 2018-11-21 Kura Oncology, Inc. Méthodes et compositions d'inhibition de l'interaction de la ménine avec les protéines mll
WO2016203405A1 (fr) * 2015-06-19 2016-12-22 Novartis Ag Composés et compositions pour inhiber l'activité de shp2
US10287266B2 (en) 2015-06-19 2019-05-14 Novartis Ag Compounds and compositions for inhibiting the activity of SHP2
WO2016203404A1 (fr) 2015-06-19 2016-12-22 Novartis Ag Composés et compositions pour inhiber l'activité de shp2
RU2604047C1 (ru) 2015-07-10 2016-12-10 Фортис Аксис, Закрытое Акционерное Общество Массажёр для воздействия на мышцы спины трех отделов позвоночника
BR112018005208B1 (pt) 2015-09-17 2023-12-12 Marvin J. Miller Compostos heterocíclicos que contêm benzilamina e composições úteis contra infecção micobacteriana
CN108779117B (zh) 2015-12-27 2021-08-31 重庆复创医药研究有限公司 一类激酶抑制剂
WO2017156397A1 (fr) 2016-03-11 2017-09-14 Board Of Regents, The University Of Texas Sysytem Inhibiteurs hétérocycliques de ptpn11
WO2017162215A1 (fr) 2016-03-25 2017-09-28 正大天晴药业集团股份有限公司 Inhibiteur de cdk pyrrolopyrimidine substituée, composition pharmaceutique le comprenant et son utilisation
CN107286150B (zh) 2016-04-11 2020-07-07 中国科学院上海有机化学研究所 N-杂环类化合物、其中间体、制备方法、药物组合物和应用
CN109475531B (zh) 2016-05-31 2021-08-17 得克萨斯州立大学董事会 Ptpn11的杂环抑制剂
KR20210019607A (ko) * 2016-06-07 2021-02-22 자코바이오 파마슈티칼스 컴퍼니 리미티드 Shp2 억제제로서 유용한 신규한 헤테로환형 유도체
KR102457146B1 (ko) * 2016-06-14 2022-10-19 노파르티스 아게 Shp2의 활성을 억제하기 위한 화합물 및 조성물
IL311645B2 (en) 2016-07-12 2025-11-01 Revolution Medicines Inc 2,5- disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines asallosteric shp2 inhibitors
EP3290412A1 (fr) 2016-08-31 2018-03-07 Università degli Studi di Siena Inhibiteurs des nucléocapsides du vih-1
WO2018057884A1 (fr) 2016-09-22 2018-03-29 Relay Therapeutics, Inc. Inhibiteurs de phosphatase shp2 et leurs procédés d'utilisation
WO2018089433A1 (fr) 2016-11-08 2018-05-17 Navitor Pharmaceuticals, Inc. Inhibiteurs de mtorc phényle et leurs utilisations
JP2020503352A (ja) 2017-01-03 2020-01-30 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド ヒト免疫不全ウイルス複製の阻害剤としてのピリジン−３−イル酢酸誘導体
CA3048340A1 (fr) * 2017-01-10 2018-07-19 Novartis Ag Combinaison pharmaceutique comprenant un inhibiteur d'alk et un inhibiteur de shp2
US20190350885A1 (en) * 2017-01-25 2019-11-21 Indiana University Research And Technology Corporation Prophylaxis treatment for acute myeloid leukemia
NZ758458A (en) * 2017-03-23 2022-07-29 Jacobio Pharmaceuticals Co Ltd Novel heterocyclic derivatives useful as shp2 inhibitors
US12428423B2 (en) 2017-04-01 2025-09-30 Shengke Pharmaceuticals (Jiangsu) Ltd. 1H-imidazo[4,5-h]quinazoline compound as protein kinase inhibitor
JP2020526557A (ja) 2017-07-12 2020-08-31 ヴァンダービルト ユニバーシティー ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト
CA3078565A1 (fr) 2017-10-12 2019-04-18 Revolution Medicines, Inc. Pyridine, pyrazine et composes de triazine utilises en tant qu'inhibiteurs allosteriques de shp2
CN118063442A (zh) 2017-10-20 2024-05-24 范德比尔特大学 毒蕈碱性乙酰胆碱受体m4的拮抗剂
CA3080941A1 (fr) 2017-12-22 2019-06-27 Dana-Farber Cancer Institute, Inc. Inhibiteurs de nek et procedes d'utilisation
SG11202006832YA (en) 2018-01-29 2020-08-28 Merck Patent Gmbh Gcn2 inhibitors and uses thereof
KR20200116481A (ko) 2018-01-29 2020-10-12 메르크 파텐트 게엠베하 Gcn2 억제제 및 이의 용도
WO2019152454A1 (fr) 2018-01-30 2019-08-08 Research Development Foundation Inhibiteurs de shp2 et méthodes d'utilisation associées
EA202091889A1 (ru) 2018-02-08 2020-10-29 Энио Фарма Конденсированные производные тиофена и их применение
BR112020017283A2 (pt) 2018-03-02 2020-12-15 Otsuka Pharmaceutical Co., Ltd Compostos farmacêuticos
JP7462951B2 (ja) 2018-03-21 2024-04-08 リャオ，シビン Ｊａｋ阻害剤

Also Published As

Publication number Publication date
JP6751203B2 (ja) 2020-09-02
EP3464272B1 (fr) 2021-12-08
US10858359B2 (en) 2020-12-08
MX388576B (es) 2025-03-20
SG10202110874TA (en) 2021-11-29
LT3464272T (lt) 2022-03-10
PT3464272T (pt) 2022-03-11
EP4108659A1 (fr) 2022-12-28
SI3464272T1 (sl) 2022-05-31
CA3026784A1 (fr) 2017-12-14
CN112250670A (zh) 2021-01-22
JP2022153616A (ja) 2022-10-12
CN112250670B (zh) 2021-06-08
KR20210019607A (ko) 2021-02-22
EA202092442A2 (ru) 2021-06-30
CY1125042T1 (el) 2023-03-24
EA202092442A3 (ru) 2021-08-31
KR20230109185A (ko) 2023-07-19
MX2021015074A (es) 2022-01-18
AU2017276457A1 (en) 2019-01-24
RS62987B1 (sr) 2022-03-31
EA202092441A1 (ru) 2021-05-21
KR20220124275A (ko) 2022-09-13
ES2908801T3 (es) 2022-05-04
CN114539273A (zh) 2022-05-27
KR20210141778A (ko) 2021-11-23
HUE057838T2 (hu) 2022-06-28
CN109311848B (zh) 2022-02-01
US20190127378A1 (en) 2019-05-02
EA201990001A1 (ru) 2019-05-31
JP2019521181A (ja) 2019-07-25
KR102218333B1 (ko) 2021-02-22
PL3464272T3 (pl) 2022-03-28
AU2017276457B2 (en) 2019-10-03
DK3464272T3 (da) 2022-02-21
EP3464272A1 (fr) 2019-04-10
PH12018550202A1 (en) 2019-10-21
CN109311848A (zh) 2019-02-05
SG11201810983PA (en) 2019-01-30
HRP20220251T1 (hr) 2022-04-29
MX2018015297A (es) 2019-08-12
JP2020189868A (ja) 2020-11-26
EP3464272A4 (fr) 2019-04-24
MX2021015073A (es) 2022-01-18
WO2017211303A1 (fr) 2017-12-14
KR20190015756A (ko) 2019-02-14

Similar Documents

Publication Publication Date Title
MA49013A (fr) Nouveaux dérivés hétérocycliques utiles en tant qu'inhibiteurs de shp2
MA45189A (fr) Nouveaux dérivés hétérocycliques utiles en tant qu'inhibiteurs de shp2
MA47125A (fr) Dérivés de pyrazole en tant qu'inhibiteurs de malt1
MA47123A (fr) Dérivés de benzooxazole en tant qu'mmunomodulateurs
EP3416964A4 (fr) Dérivés de carboxamide utiles en tant qu'inhibiteurs de rsk
MA46981A (fr) Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine
MA40774A (fr) Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38
MA51878A (fr) Composés d'aminothiazole en tant qu'inhibiteurs de c-kit
MA45153A (fr) Dérivés de carbonucléosides substitués utiles en tant qu'agents anticancéreux
MA46339A (fr) Dérivés de cyanopyrrolidine ayant une activité en tant qu'inhibiteurs de l'usp 30
MA43169A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma
MA42659A (fr) Dérivés hétéroaryle utilisés en tant qu'inhibiteurs de parp
MA53150A (fr) Composés de benzimidazole en tant qu'inhibiteurs de c-kit
MA45244A (fr) Pyridines substituées utilisées en tant qu'inhibiteurs de dnmt1
ME03776B (fr) Dérivés de pyridin-2-(1h)-one-quinolinone en tant qu'inhibiteurs d'isocitrate déshydrogénase
MA55194A (fr) Composés hétérocycliques en tant qu'immunomodulateurs
MA41140A (fr) Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg
MA47086A (fr) Dérivés de dihydropyrimidine-carboxamide bicycliques utilisés en tant qu'inhibiteurs de rho-kinase
MA54567A (fr) Pyridine et composés de pyridimine en tant qu'inhibiteurs de pi3k-gamma
MA44498A (fr) Dérivés d'indoline substituée utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue
MA42592A (fr) Utilisation de dérivés de 2-(pyrazolopyridin-3-yl) pyrimidine en tant qu'inhibiteurs de jak
EP2970119A4 (fr) Nouveaux dérivés d'indole utiles en tant qu'agents antidiabétiques
MA44502A (fr) Dérivés d'indole substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue
MA46878A (fr) Composés de benzodiazolium en tant qu'inhibiteurs d'enac
MA41341A (fr) Dérivés indole utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue